Volume 4.10 | Mar 19

Hematopoiesis News 4.10 March 19, 2013
Hematopoiesis News

     In this issue: Publications | ReviewsIndustry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
Differential Stem- and Progenitor-Cell Trafficking by Prostaglandin E2
Scientists showed that inhibition of endogenous prostaglandin E2 by non-steroidal anti-inflammatory drug treatment in mice results in modest hematopoietic stem cell egress from the bone marrow. Surprisingly, this was independent of the SDF-1-CXCR4 axis implicated in stem-cell migration. [Nature]
Abstract | Press Release

Free Wallchart: Identification Of Colonies Derived From Mouse Hematopoietic Progenitors
PUBLICATIONS (Ranked by impact factor of the journal)


A KRAB/KAP1-MicroRNA Cascade Regulates Erythropoiesis through Stage-Specific Control of Mitophagy
During hematopoiesis, lineage- and stage-specific transcription factors work in concert with chromatin modifiers to direct the differentiation of all blood cells. Scientists explored the role of KRAB-containing zinc finger proteins and their cofactor KAP1 in this process. [Science] Abstract

GSK3β Regulates Physiological Migration of Stem/Progenitor Cells via Cytoskeletal Rearrangement
While glycogen synthase kinase-3β (GSK3β) is known to participate in hematopoietic stem and progenitor cell (HSPC) proliferation, the authors revealed an unexpected role in the preferential regulation of CXCL12-induced migration and steady-state egress of murine HSPCs, including long-term repopulating HSCs, over mature leukocytes. [J Clin Invest] Full Article

Interferon-Gamma Impairs Proliferation of Hematopoietic Stem Cells in Mice
Researchers demonstrated that the pro-inflammatory cytokine interferon-γ (IFN-γ) impairs maintenance of hematopoietic stem cells (HSCs) by directly reducing their proliferative capacity and that IFN-γ impairs restoration of HSC numbers upon viral infection. [Blood] Abstract

Maintenance of the Hematopoietic Stem Cell Pool in Bone Marrow Niches by EVI1-Regulated GPR56
Acute myeloid leukemia (AML) with high ecotropic viral integration site-1 expression (EVI1high AML) is classified as a refractory type of leukemia with a poor prognosis. To provide new insights into the prevention and treatment of this disease, scientists identified the high expression of EVI1-regulated G protein-coupled receptor 56 (GPR56) and the association of high cell adhesion and anti-apoptotic activities in EVI1high AML cells. [Leukemia] Abstract

Pim1 Serine/Threonine Kinase Regulates the Number and Functions of Murine Hematopoietic Stem Cells
Investigators generated PIM1 transgenic mice (Pim1-Tx) over-expressing human PIM1 driven by vav hematopoietic promoter/regulatory elements. Compared to wild-type littermates, Pim1-Tx mice showed enhanced hematopoiesis as demonstrated by increased numbers of LinSca-1+c-Kit+ hematopoietic stem/progenitor cells (HSCs) and cobblestone area forming cells, higher BrdU incorporation in long-term HSC population, and a better ability to reconstitute lethally irradiated mice. [Stem Cells] Abstract

Introduction of Exogenous T-Cell Receptors into Human Hematopoietic Progenitors Results in Exclusion of Endogenous T-Cell Receptor Expression
Scientists successfully generated MART-1-specific CD8 T cells from genetically modified human hematopoietic stem cells in a humanized mouse model. [Mol Ther] Abstract

Lenograstim Compared to Filgrastim for the Mobilization of Hematopoietic Stem Cells in Healthy Donors
The authors compared the efficacy of lenograstim and filgrastim in terms of number of circulating CD34+ cells/μL during the fifth day of granulocyte-colony-stimulating factor administration, the number of days of apheresis required to obtain the target cell dose, the median of CD34+ cells collected on the first day of apheresis, or the median number of total CD34+ cells collected at the end of the procedure, in a series of 146 healthy donors undergoing hematopoietic stem cell mobilization for allogeneic transplantation. [Transfusion] Abstract


Outcomes of Transplantation Using Various Hematopoietic Cell Sources in Children with Hurler’s Syndrome after Myeloablative Conditioning
Event free survival (EFS) after HLA matched sibling donor and 6/6 matched unrelated-cord blood (CB) were similar at 81%, 66% after 10/10 HLA matched unrelated donor (UD) and 68% after 5/6 matched CB. EFS was lower after transplantation of 4/6 matched unrelated CB and HLA mismatched UD. [Blood]
Abstract | Press Release

Nilotinib Is Associated with a Reduced Incidence of BCR-ABL Mutations versus Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
In patients with chronic myeloid leukemia, BCR-ABL mutations contribute to resistance to tyrosine kinase inhibitor therapy. Researchers examined the occurrence of treatment-emergent mutations and their impact on response in patients from the ENESTnd Phase III trial. [Blood] Abstract

STEMvision(TM) Instrument

Current Concepts in Bone Marrow Microenvironmental Regulation of Hematopoietic Stem and Progenitor Cells
Throughout development as well as in adulthood, the local microenvironment of hematopoietic stem and progenitor cells plays an instructive role in stem cell fate. The authors discuss recent reports on these regulatory interactions. [Stem Cell] Abstract | Full Article

World Stem Cell and Regenerative Medicine Congress

Cryo-Cell International Affiliate Earns Patent for Processing Umbilical Cord Blood for Therapeutic Use in Treating Neurodegenerative Diseases and Spinal Cord and Brain Injuries
A patent issued to Saneron CCEL Therapeutics, Inc. and the University of South Florida may facilitate increased use of cord blood stem cells in medical therapies, according to Linda Kelley, Ph.D., chief scientific officer with Cryo-Cell International. Cryo-Cell is a major investor in Saneron CCEL Therapeutics. [Cryo-Cell International, Inc.] Press Release

Regen BioPharma Receives IND # from FDA for HemaXellerate
Regen BioPharma, Inc. announced issuance of IND number 15376 for its proposed Phase I/II clinical trial evaluating use of its stem cell product, HemaXellerate, for treatment of aplastic anemia. [Marketwire]
Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)
Center for Biologics Evaluation and Research (United States)
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW ICCSCE 2013: International Conference on Cell and Stem Cell Engineering
September 26-27, 2013
Rome, Italy

Visit our events page to see a complete list of events in the hematopoietic community.


Postdoctoral Position – Stem Cell Research (University of Washington)

Postdoctoral Position – Hematopoietic Stem Cells and Stem Cell Aging (Cincinnati Children’s Hospital Research Foundation)

Lecturer or Reader – Associate Professor (University of Reading)

Research Assistant – Stem Cell & Leukemia Epigenetics (King’s College London)

Postdoctoral Position – Bioinformatics and Stem Cell Biology (University of Texas at Houston)

Postdoctoral Position – Stem Cells and Cancer (Tsinghua University)

Cord Blood Laboratory Manager (Puget Sound Blood Center)

Stem Cell Program Director (Cancer Treatment Centers of America)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Hematopoiesis Cell News: Archives | Events | Contact Us

Suite 201 – 375 West Fifth Avenue
Vancouver, BC V5Y 1J6, Canada